Search

Displaying results 5171 - 5180 of 10000 in total
  1. Drug

    OPC-51803

    go.drugbank.com/drugs/DB05838
    Experimental

    It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence. … It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states.

  2. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  3. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.

  4. Drug

    Glypromate

    go.drugbank.com/drugs/DB05633
    Experimental

    In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by IV

  5. Drug

    AT-7519

    go.drugbank.com/drugs/DB08142
    Investigational

    AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

    Synonyms: 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  6. Drug

    TC-5231

    go.drugbank.com/drugs/DB05333
    Experimental

    TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine. … TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder).

  7. Drug

    CPG 10101

    go.drugbank.com/drugs/DB05530
    Investigational

    CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.

  8. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility … of the GI tract is severely impaired.

  9. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  10. Drug

    Mimosine

    go.drugbank.com/drugs/DB01055
    Experimental

    Mimosine is an antineoplastic alanine-substituted pyridine derivative isolated from _Leucena glauca_.